Latest News and Press Releases

Chicago, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The global live streaming market was valued at 135.7 billion in 2024 and is expected to reach US$ 1,234.2 billion by 2033, growing at a CAGR of 27.8% from...

Alpha Modus partners with Tickets For Less to integrate live event ticketing into AlphaCash, expanding consumer utility ahead of national kiosk rollout.

A global study shows biometric and document fraud have become the most common identity verification threats in crypto (35% each).

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...

The group’s unaudited consolidated revenue decreased in the fourth quarter of 2025 by 2% year-over-year to €3,525 thousand (Q4 2024: €3,598 thousand). Textmagic platform's revenue is affected by...

Wegovy Pill vs Wegovy Shot: Daily oral vs weekly injectable semaglutide differences following 2026 FDA approval. Ro.co access pathway examined.

Vancouver, BC, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc.'s (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that the Company has granted an aggregate 75,000 stock...

- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for...

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants...